evinacumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 5449 1446419-85-7

Description:

MoleculeDescription

Molfile

Synonyms:

  • evinacumab
  • evinacumab-dgnb
  • evkeeza
  • REGN1500
Evinacumab-dgnb is a recombinant human monoclonal antibody that binds to and inhibits ANGPTL3. ANGPTL3 is a member of the angiopoietin-like protein family that is expressed primarily in the liver and plays a role in the regulation of lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL). Evinacumab-dgnb inhibition of ANGPTL3 leads to reduction in LDL-C, HDL-C, and triglycerides (TG). Evinacumab-dgnb reduces LDL-C independent of the presence of LDL receptor (LDLR) by promoting very low-density lipoprotein (VLDL) processing and clearance upstream of LDL formation. Evinacumab-dgnb blockade of ANGPTL3 lowers TG and HDL-C by rescuing LPL and EL activities, respectively.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 17, 2021 EMA Regeneron Ireland Designated Activity Company (DAC)
Feb. 11, 2021 FDA REGENERON PHARMACEUTICALS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AX17 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Other lipid modifying agents
FDA EPC N0000193915 Angiopoietin-like 3 Inhibitor
FDA MoA N0000193916 Angiopoietin-like 3 Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Homozygous familial hypercholesterolemia indication 238078005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Angiopoietin-related protein 3 Secreted INHIBITOR Kd 9.04 DRUG LABEL DRUG LABEL

External reference:

IDSource
D11753 KEGG_DRUG
T8B2ORP1DW UNII
C4508522 UMLSCUI
CHEMBL3545191 ChEMBL_ID
DB15354 DRUGBANK_ID
8717 IUPHAR_LIGAND_ID
018635 NDDF
1149149009 SNOMEDCT_US
1149184008 SNOMEDCT_US
4040110 VANDF
4040111 VANDF
2478335 RXNORM
343531 MMSL
39317 MMSL
d09713 MMSL
C000621590 MESH_SUPPLEMENTAL_RECORD_UI
10013 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Evkeeza HUMAN PRESCRIPTION DRUG LABEL 1 61755-010 INJECTION, SOLUTION, CONCENTRATE 150 mg INTRAVENOUS BLA 29 sections
Evkeeza HUMAN PRESCRIPTION DRUG LABEL 1 61755-010 INJECTION, SOLUTION, CONCENTRATE 150 mg INTRAVENOUS BLA 29 sections
Evkeeza HUMAN PRESCRIPTION DRUG LABEL 1 61755-010 INJECTION, SOLUTION, CONCENTRATE 150 mg INTRAVENOUS BLA 29 sections
Evkeeza HUMAN PRESCRIPTION DRUG LABEL 1 61755-013 INJECTION, SOLUTION, CONCENTRATE 150 mg INTRAVENOUS BLA 29 sections
Evkeeza HUMAN PRESCRIPTION DRUG LABEL 1 61755-013 INJECTION, SOLUTION, CONCENTRATE 150 mg INTRAVENOUS BLA 29 sections
Evkeeza HUMAN PRESCRIPTION DRUG LABEL 1 61755-013 INJECTION, SOLUTION, CONCENTRATE 150 mg INTRAVENOUS BLA 29 sections